Reversible Therapeutic Complexes for Targeted Cancer Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer, such as activating T-cells, are laborious, time-consuming, and limited by the number of target-specific cells that can be expanded, leading to inefficient targeting and side effects, particularly in treating relapsed acute myeloid leukemia (AML), where treatment options are scarce and often ineffective.
Innovation Solution
A complex comprising a targeting unit and a therapeutic unit, where the targeting unit is conjugated to a first linker and the therapeutic unit to a second linker, forming a reversible complex that can interact via temperature, pH, enzymatic, or ionic changes, allowing specific binding to biological markers on target cells, enhancing the therapeutic agent's activity and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapy approaches are used to activate and expand T-cells, then therapeutic efficacy may be improved, but the process becomes laborious and time-consuming
Solution Approach 1:
The patent segments the immunotherapy process by separating the T-cell expansion function from the targeting function. Instead of expanding patient-specific T-cells over months, the invention uses off-the-shelf TCR-transduced T-cells that are pre-expanded and ready for immediate use, dramatically reducing preparation time while maintaining therapeutic efficacy through the specialized TCR engineering approach.
Solution Approach 2:
The patent applies preliminary action by pre-engineering and pre-expanding T-cells with specific TCRs in advance, creating an off-the-shelf product that can be immediately administered. This eliminates the need for time-consuming in-vivo expansion processes and allows rapid treatment initiation, particularly benefiting patients with relapsed AML who need quick intervention.
2Quantity of substance
If T-cells are expanded to achieve therapeutically relevant populations, then therapeutic potency is improved, but the process is limited by the number of target-specific cells in the starting sample
Solution Approach 1:
The patent uses copying by creating T-cells that carry engineered TCRs specific to the target antigen, rather than relying on the limited number of naturally occurring target-specific T-cells in the patient sample. The TCR gene is copied into the T-cell genome, ensuring each T-cell expresses the desired specificity regardless of the starting material's composition.
Solution Approach 2:
The patent applies parameter changes by modifying the T-cell population through genetic engineering with specific TCRs. This changes the fundamental parameter of T-cell specificity from being determined by natural occurrence to being determined by engineered insertion, allowing expansion to large numbers of target-specific cells regardless of the starting sample's initial composition.
3Productivity
If accessory cells are used in the T-cell expansion process, then expansion efficiency is improved, but the risk of contamination increases
Solution Approach 1:
The patent extracts and eliminates the need for accessory cells from the expansion process. By using TCR-transduced T-cells that can self-expand or be expanded with minimal external help, the invention removes the contamination risk associated with introducing accessory cells from external sources, while maintaining expansion efficiency through the engineered T-cell system itself.
4Area of stationary object
If therapeutic agents are administered systemically, then broad coverage is achieved, but off-target side effects occur
Solution Approach 1:
The patent applies local quality by engineering T-cells with TCRs that are highly specific to particular antigenic peptides presented by MHC molecules. This gives the T-cells localized specificity - they only recognize and attack cells presenting the target antigen, while leaving other cells untouched. The specificity is built into the TCR's structural and functional properties, ensuring precise target recognition.
Solution Approach 2:
The patent uses the MHC antigen-presenting complex as an intermediary that mediates between the T-cell and the target cell. The TCR does not directly recognize the target antigen protein, but rather recognizes the antigen peptide when presented by MHC on the target cell surface. This intermediary mechanism ensures high specificity and reduces off-target effects, as the T-cell only activates when the correct antigen-MHC complex is present.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enhances the activity of therapeutic agents at target cells, achieving greater efficacy with reduced side effects and enabling more effective treatment of cancer, including relapsed AML, by specifically delivering therapeutic agents to cancer cells while minimizing off-target activity.
Implementation Method 1
the first linker is a first polynucleotide and the second linker is a second polynucleotide, wherein the reversible complex forms via the first polynucleotide hybridizing to the second polynucleotide based on sequence complementarity
Data Source
AI summary
The disclosure provides complexes comprising targeting units, methods for their production, and methods for their use. In some embodiments, complexes comprise therapeutic agents complexed with targeting units. In some embodiments, complexes comprise cells complexed with targeting units. In view of the foregoing, there is a need for improved modalities for targeting of therapeutics, in the area of immunotherapy and others. The present disclosure addresses these needs, and provides additional advantages as well.